ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Stability of T Reg with Combination of mTOR Inhibitors with Belatacept in Reducing Risk of Acute Rejection in Kidney Transplant

J. Shoji, J. Leung, Q. Tang, F. Vincenti

University of California San Francisco (UCSF), San Francisco, CA

Meeting: 2020 American Transplant Congress

Abstract number: 227

Keywords: Co-stimulation, Immunosuppression, Kidney transplantation, Rejection

Session Information

Date: Saturday, May 30, 2020

Session Name: Novel Tools to Assess Immunosuppressive Efficacy

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:03pm-4:15pm

Location: Virtual

Related Abstracts
  • The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy
  • mTOR Inhibition Diminishes Peripheral Blood CD8+CD28–CD38hi Effector/Memory T Cells and Facilitates Resolution of Belatacept-Refractory Kidney Rejection.

*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and improve long term outcomes. In view of experimental studies showing synergy between costimulatory blockade and mTOR inhibitors, we developed a belatacept regimen incorporating everolimus to reduce acute rejection. We performed mechanistic studies to analyze circulatory T cells by flow and functional assays pre-and post-transplant to identify favorable lymphocyte profile that may predict those at lower risk of acute rejection in belatacept-based regimen.

*Methods: We prospectively enrolled 65 kidney transplant recipients (31 deceased; 34 living donors) at our center to receive denovo belatacept from September 2012 to June 2018. PBMCs were collected prior to transplantation, 3 months, and 6 months post-transplant. All patients received thymoglobulin for induction with belatacept 10mg/kg administered on POD 1, 4, 14, 28, 56, and 84. Monthly maintenance dose of 5mg/kg was given starting week 16. Patients were started initially on MPA but were converted to everolimus after 1 month, and all patients were maintained on prednisone.

*Results: In the first 12 months post-transplant, 16.9% developed acute rejection: 2 patients were noted to have ACR 1a, 1 with ACR 2a, 6 with ACR 2b, 1 with AMR, and 1 with simultaneous ACR 1a and AMR (at 9 months). All 11 rejections occurred in those who were on MPA and not on mTORi. In addition, 12 patients were found to have borderline rejection on protocol biopsies (7 on mTORi, 5 on MPA). 42 patients did not have any inflammation on biopsies. Patients who had biopsy-proven rejection or borderline changes had significantly higher percentages of CD8+CD28–T cells, and those who had rejection with low CD8+CD28- were found to have high CD2hiCD28hiin CD8+CD45RO+ T cells. Helios+Foxp3+ Treg population was higher at 3 months and 6 months post-transplant in everolimus group compared to mycophenolate group.

*Conclusions: Acute rejection in belatacept-based regimen can be reduced by combining belatacept with mTORi due to it’s synergistic effect on memory CD8+CD28-CD38+ cells that are refractory to costimulatory blockade. Pretransplant immunotyping of circulating T cells to identify those with low percentage of CD8+CD28- & CD2hiCD28hi in CD8+CD45RO+ may identify patients who will be at lowest risk of rejection on belatacept. The stability of T regs in everolimus-based regimen post-transplant also may contribute to reducing acute rejection.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Shoji J, Leung J, Tang Q, Vincenti F. Stability of T Reg with Combination of mTOR Inhibitors with Belatacept in Reducing Risk of Acute Rejection in Kidney Transplant [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/stability-of-t-reg-with-combination-of-mtor-inhibitors-with-belatacept-in-reducing-risk-of-acute-rejection-in-kidney-transplant/. Accessed March 4, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.